🔎 Trials Near Me

Akèy › Osteyosakòm › Massachusetts › Boston

Etid klinik pou Osteyosakòm nan Boston, MA

9 etid pou Osteyosakòm ap chèche patisipan nan sit nan ak bò kote Boston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

Ap rekriteFaz 2
  • Dana-Farber Cancer Institute, Boston
Laj 12 a 39 · Tout sèks · Mizajou Sep 29, 2026 · NCT04616560

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Ap rekriteFaz 1/2
  • Dana-Farber Cancer Institute, Boston
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

Ap rekriteFaz 3
  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
Jiska laj 50 · Tout sèks · Mizajou Aug 25, 2026 · NCT05235165

SPEARHEAD-3 Pediatric Study

Ap rekriteFaz 1/2
  • Dana Farber Cancer Institute, Boston
Laj 2 a 21 · Tout sèks · Mizajou Aug 11, 2026 · NCT05642455

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Ap rekriteEtid obsèvasyon
  • Dana-Farber Cancer Institute, Boston
Tout laj · Tout sèks · Mizajou May 18, 2026 · NCT01790152

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

Ap rekriteFaz 1/2
  • Dana Farber Cancer Institute, Boston
Laj 12 ak plis · Tout sèks · Mizajou May 1, 2026 · NCT07357519

Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

Ap rekriteFaz 2
  • Dana-Farber Cancer Institute, Boston
Laj 12 ak plis · Tout sèks · Mizajou Apr 17, 2026 · NCT05019703

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Ap rekriteFaz 1/2
  • Boston Children's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
  • Brigham and Women's Hospital, Boston
Laj 12 a 49 · Tout sèks · Mizajou Feb 19, 2026 · NCT06709495

Etid Osteyosakòm nan lòt vil

Lòt etid nan Boston

Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.